Diagnosis & Disease Information

Survival Data Announced for Rindopepimut in Glioblastoma

Celldex Therapeutics announced three-year survival data from the Phase 2 rindopepimut clinical program in EGFRvIII-positive glioblastoma—a more aggressive form of glioblastoma typically associated with reduced long-term survival in comparison to the glioblastoma population as a whole.

Next post in Brain Cancer